← All trials
NCT04483024
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 1, 2018
- Primary completion
- Oct 31, 2019
- Completion date
- Dec 1, 2019
- First posted
- Jul 23, 2020
- Last posted
- Jul 29, 2020
- Enrollment
- 160
- Arms / groups
- 4 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Cerebos Pacific LimitedLead sponsor
- Chang Gung UniversityOverall official - principal investigator
- Chang Gung UniversityCollaborator
- Cerebos Pacific LimitedSponsor investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.